Oppenheimer analyst Andreas Argyrides lowered ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)July 21, 2025 6:55 AM BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 21, 2025 6:03 AM Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'July 18, 2025 2:19 PM Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'July 18, 2025 9:42 AM Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)July 18, 2025 9:33 AM Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)July 18, 2025 8:59 AM William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'July 18, 2025 8:58 AM Leerink Partners Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)July 18, 2025 8:55 AM